GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Smith & Nephew SNATS SNN · USD

Health Care · US listing · 🇺🇸 United States

Compare

31.05

-0.32%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Smith & Nephew SNATS

Its shares trade under the ticker SNN. It has been listed since 16 November 1999. In the fiscal year to 31 December 2025, it reported revenue of $6.16bn and net income of $625.0m. At that date it held total assets of $10.46bn and shareholders' equity of $5.29bn.

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
16 Nov 1999
Employees
17,530
Head office
BUILDING 5, CROXLEY PARK, WATFORD, HERTFORDSHIRE, WD18 8YE
Classification
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Filer status
Large accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Smith & Nephew operates in three key medical segments with strong product portfolios.
  • Orthopaedics and Advanced Wound Management drive significant revenue streams globally.
  • The company has a large employee base of 17,530 supporting global operations.

Weaknesses

  • Smith & Nephew's headquarters city is Watford, UK, which may limit local market access.
  • The company's listing date of 1999 may indicate outdated business strategies.
  • US operations face challenges in the competitive Health Care sector.

Opportunities

  • Expanding into emerging markets in Asia could boost growth opportunities.
  • The Sports Medicine & ENT segment shows potential for innovation and market expansion.
  • Advanced Wound Management products are in high demand globally.

Threats

  • Intense competition in the US Health Care market threatens market share.
  • Regulatory changes in the UK could impact operations and product approvals.
  • The global economic downturn may reduce healthcare spending on medical devices.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.